Nova Scotia Duck Tolling Retrievers are cheerful, athletic dogs with a devoted fan base and a serious health problem: they develop Addison’s disease at rates far higher than most other breeds. The autoimmune disorder quietly destroys the adrenal glands, cutting off hormones the body cannot live without. For years, veterinary geneticists suspected a strong hereditary component but could not pinpoint the gene responsible. A study published in Scientific Reports in early 2026 has changed that, identifying a recessive variant in the gene RESF1 as a major driver of juvenile-onset Addison’s in the breed. A genetic test based on the finding is reported to be available, and researchers say the discovery could eventually inform the study of autoimmune adrenal failure in people.
What the study found
A research team performed a genome-wide association scan across affected and unaffected tollers and detected a strong signal on canine chromosome 27. The lead marker reached a p-value of 6.96 × 10⁻¹³, a level of statistical significance that far exceeds the threshold used in genomic studies. Fine-mapping narrowed the signal to a single missense change in RESF1, a gene involved in epigenetic regulation of the genome.
Dogs that carried two copies of the variant were heavily overrepresented among those diagnosed with Addison’s, while dogs with just one copy appeared clinically healthy. That pattern is consistent with classic recessive inheritance: a single working copy of the gene is enough to keep the adrenal glands functioning, but two faulty copies leave the immune system free to attack.
Several of the affected young dogs showed signs of multiple autoimmune syndrome, a condition in which the immune system targets more than one endocrine gland at the same time. Veterinary case reports have previously described tollers with lymphocytic inflammation in the pituitary, adrenal, and thyroid glands simultaneously, a pattern that mirrors human polyglandular autoimmune syndromes.
To rule out the possibility that the RESF1 variant was simply a common, harmless quirk shared across many breeds, the team checked it against the Dog Biomedical Variant Database Consortium, a resource built from whole-genome sequences of 582 dogs and eight wolves spanning dozens of breeds. The variant was extremely rare outside affected tollers, strengthening the case that it plays a direct role in disease rather than tagging along as a neutral passenger in the genome.
The biology behind the breakdown
Separate pathology work has filled in the biological story connecting genetic susceptibility to gland destruction. Immunophenotyping of adrenal tissue from dogs with primary hypoadrenocorticism has revealed T-cell-predominant infiltrates in the adrenal cortex, the hallmark of an autoimmune attack. Over time, that inflammatory assault leads to progressive adrenocortical atrophy: the gland shrinks, hormone output drops, and without treatment the dog faces a life-threatening crisis.
When genetic association, population-level rarity, and tissue-level pathology all converge on the same explanation, the overall case for a pathogenic variant becomes substantially stronger, even before detailed biochemical experiments spell out every molecular step.
A breeding tool that is already in use
For toller breeders, the practical payoff is immediate. The study authors have indicated that a genetic test for the RESF1 variant is commercially available, though no direct link to the test or to an official institutional announcement has been published online as of May 2026. Breeders can identify carriers and affected homozygotes before making mating decisions, reducing the chance of producing puppies destined to develop Addison’s.
The recommended strategy is not to remove every carrier from the gene pool. Tollers are a relatively small breed, and aggressive culling of carriers could shrink genetic diversity and raise the risk of other inherited problems. Instead, geneticists advise avoiding carrier-to-carrier pairings while retaining healthy carriers in carefully planned breedings with clear (non-carrier) mates. That approach lowers disease incidence gradually without bottlenecking the breed.
Breed clubs have estimated Addison’s incidence in tollers at roughly one to two percent, though no large-scale genotyping survey has yet confirmed how many carriers exist worldwide. As more dogs are tested, those numbers will sharpen, and breeding recommendations may be updated accordingly.
What this could mean for human medicine
The research team has described RESF1 as a candidate gene for human Addison’s disease and multiple autoimmune syndrome research. The logic is straightforward: if a variant in this gene can trigger autoimmune adrenal destruction in dogs, rare variants in the same pathway might contribute to the same disease in people. Autoimmune Addison’s in humans is uncommon, affecting roughly one in 10,000 people in Western populations, and its genetic architecture remains poorly mapped beyond associations with the HLA region of the immune system.
Dogs offer a useful model because purebred populations concentrate risk alleles in ways that make them easier to detect statistically. A variant that would be nearly invisible in a genetically diverse human cohort can stand out sharply in a breed with a limited founder population. That is exactly what happened here.
Still, the translational promise is early-stage. No functional experiments have yet shown how the RESF1 missense change alters protein behavior, disrupts chromatin regulation, or shifts immune tolerance at the cellular level. No clinical trials or formal research programs targeting the human RESF1 gene have been publicly announced as of May 2026. Bridging the gap between a canine candidate gene and a validated human disease mechanism typically requires years of independent replication in human cohorts, functional cell biology, and careful cross-species comparison.
Open questions for tollers and autoimmune science
Several open questions will shape how far this discovery reaches. The RESF1 variant explains a significant share of Addison’s risk in tollers, but it has not been shown to account for every case. Some affected dogs may carry different, still-unidentified risk alleles, and some homozygous carriers may never develop clinical disease. Like most autoimmune conditions, Addison’s in dogs probably involves a web of genetic and environmental factors, including background immune genes, infections, and physiological stress, that were not dissected in this study.
Larger genotyping surveys across the global toller population will clarify the variant’s true frequency and help breed clubs calibrate their testing guidelines. Functional studies in cell and animal models will need to show precisely how the variant disrupts RESF1’s normal role and tips the immune system toward self-attack. And human geneticists will need to look for rare RESF1 variants in cohorts of people with idiopathic Addison’s disease to see whether the canine finding translates across species.
For now, the most concrete outcome belongs to the breed community. Toller owners and breeders have a validated genetic test that can guide responsible mating decisions and, over time, reduce the burden of a disease that has shadowed the breed for decades. For the wider world of autoimmune research, the RESF1 finding offers something almost as valuable: a specific, testable hypothesis in a field where such hypotheses have been hard to come by.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
